Co-Authors
This is a "connection" page, showing publications co-authored by Christine Bestvina and Robert Cameron.
Connection Strength
0.314
-
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
Score: 0.202
-
Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges. Front Oncol. 2026; 16:1779081.
Score: 0.060
-
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 07; 19(7):1108-1116.
Score: 0.052